ARDX Live signals | Maximize Profits with Getagraph.com

BUY 52437 min ago

@ $7.87

Issued: 21 Mar 2024 @ 14:10

Return: -18.43%

Previous signal: Mar 21 - 13:13

Previous signal: Sell

Return: -0.76 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally...

Stats
Today's Volume	5.46M
Average Volume	5.53M
Market Cap	1.49B
EPS	$0 ( 2024-02-22 )
Next earnings date	( $-0.130 ) 2024-05-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-21.40
ATR14	$0.0100 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	Raab Michael	Sell	7 500	Common Stock
2024-04-01	Raab Michael	Sell	1 518	Common Stock
2024-03-25	Kelliher Mike	Buy	205 000	Stock Option (Right to Buy)
2024-03-25	Kelliher Mike	Buy	160 000	Common Stock
2024-03-25	Kelliher Mike	Buy	0

INSIDER POWER
66.45
Last 99 transactions
Buy: 4 000 095 \| Sell: 852 364

Volume Correlation

Long: -0.31 (neutral)

Short: -0.56 (weak negative)

Signal:(35.158) Neutral

Ardelyx Inc Correlation

10 Most Positive Correlations
MLAI	0.964
KAII	0.959
FRSG	0.959
TCMD	0.956
ACQR	0.954
NVSA	0.952
GLLI	0.952
ARRW	0.952
TBSA	0.951
CPAQ	0.95

10 Most Negative Correlations
CSSEP	-0.96
EQBK	-0.957
FCBC	-0.951
MBOT	-0.949
DRUG	-0.945
BMRA	-0.944
EVLO	-0.942
FSFG	-0.942
SPFI	-0.941
BWB	-0.94

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ardelyx Inc Correlation - Currency/Commodity

0.85
( strong )

0.81
( strong )

0.00
( neutral )

0.81
( strong )

0.00
( neutral )

-0.37
( neutral )

Ardelyx Inc Financials

Annual	2023
Revenue:	$124.46M
Gross Profit:	$106.66M (85.70 %)
EPS:	$-0.300

FY	2023
Revenue:	$124.46M
Gross Profit:	$106.66M (85.70 %)
EPS:	$-0.300

FY	2022
Revenue:	$52.16M
Gross Profit:	$48.04M (92.11 %)
EPS:	$-0.420

FY	2021
Revenue:	$10.10M
Gross Profit:	$9.10M (90.10 %)
EPS:	$-1.520

Financial Reports:

No articles found.

Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Realtime updates for Ardelyx Inc [ARDX]

Upcoming Earnings Alert